MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.24.00576

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.

Mercinelli Chiara, Moschini Marco, Cigliola Antonio, Mattorre Benedetta, Tateo Valentina, Basile Giuseppe, Cogrossi Laura L, Maiorano Brigida A, Patanè Damiano A, Raggi Daniele, Pastorino Giovanni L, Re Chiara, Colecchia Maurizio, Lucianò Roberta, Colombo Renzo, Brembilla Giorgio, De Cobelli Francesco, Briganti Alberto, Pavlick Dean C, Ross Jeffrey S, Montorsi Francesco, Bellone Matteo, Necchi Andrea

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, followed by radical cystectomy (RC) and postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer (MIBC).

PATIENTS AND

METHODS

Eligible patients had an Eastern Cooperative Oncology Group performance status of ≤1 and a T2-4aN0-1M0 stage with >50% urothelial carcinoma histology and were ineligible for or refused cisplatin-based chemotherapy. Patients received four cycles of nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m2 once on days 1 and 8, every 3 weeks, followed by RC, and then adjuvant nivolumab 360 mg once every 3 weeks × 13 cycles. The primary end point was the pathologic complete response (CR) rate (ypT0N0). Secondary end points were major pathologic response (ypT≤1N0), safety, event-free survival (EFS), and overall survival.

RESULTS

Thirty-one patients were enrolled from December 2021 to June 2023; 19 (61.3%) had a cT2 stage, two (6.5%) had N1 stage, and 16 (51.6%) had a variant histology. Five patients (16.1%) received less than four full courses of neoadjuvant treatment because of treatment-related adverse events (TRAEs). Grade 3/4 TRAEs occurred in eight patients (25.8%). Twenty-eight patients underwent RC, and three refused RC after evidence of clinical CR and received a redo transurethral resection of the bladder tumor (reTURBT). The trial met its primary end point: 10 patients (32.3%; 95% CI, 16.7 to 51.4) achieved an ypT0N0 response. By including those who underwent reTURBT, 22 (70.9%; 95% CI, 55 to 87) achieved an ypT≤1N0-x response. After a median follow-up of 12 months (range, 5-22), two patients had a disease relapse after surgery. The 12-month EFS was 89.8% (95% CI, 79.5 to 100).

CONCLUSION

To our knowledge, the first results from NURE-Combo trial suggest that this combination could expand the therapeutic opportunities of immune-chemotherapy in patients with MIBC.

Для цитирования: Mercinelli Chiara, Moschini Marco, Cigliola Antonio, Mattorre Benedetta, Tateo Valentina, Basile Giuseppe, Cogrossi Laura L, Maiorano Brigida A, Patanè Damiano A, Raggi Daniele, Pastorino Giovanni L, Re Chiara, Colecchia Maurizio, Lucianò Roberta, Colombo Renzo, Brembilla Giorgio, De Cobelli Francesco, Briganti Alberto, Pavlick Dean C, Ross Jeffrey S, Montorsi Francesco, Bellone Matteo, Necchi Andrea. First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. DOI: 10.1200/jco.24.00576.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.